/PRNewswire/ First Patient Dosed in Optimize-1 Phase II "We continued to make great strides in the third quarter of 2021. The first patient was dosed in.
Alligator Bioscience AB: Interim report January-June 2021 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the annual general meeting was held in the company this day. In light of.
High activity during the first quarter So far, 2021 has been characterized by high activity, with a research collaboration that validates our Discovery concept, and good progress of our clinical programs, with ATOR-1017 and mitazalimab entering clinical efficacy studies this year.
Malin Carlsson, Interim CEO Alligator Bioscience AB
SIGNIFICANT EVENTS JANUARY-MARCH
Pipeline:
New preclinical data were released in an abstract for a poster presentation at the AACR Annual Meeting 2021, demonstrating that mitazalimab synergizes with chemotherapy.
Company:
Søren Bregenholt was appointed as new CEO to strengthen Alligator s business development activities and clinical progress on an international level.
Oversubscribed rights issue generated proceeds of SEK 86 milli
Alligator Bioscience AB: Interim report January-March 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.